Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Pharmacol. Ther.

Title: Clinical pharmacology and therapeutics

ISSN (Electronic): 1532-6535

ISSN (Print): 0009-9236

Publication date (Electronic): Jul 2015

Volume: 98

Issue: 1

Affiliations

[1 ] Division of Nephrology Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.

[2 ] Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.

[3 ] Division of Nephrology and Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

[4 ] Department of Genetics, Stanford University, Stanford, California, USA.

[5 ] Department of Biomedical Informatics, Vanderbilt University, Nashville, Tennessee, USA.

[6 ] Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.

[7 ] Center for Pharmacogenomics, School of Medicine, The Ohio State University, Columbus, Ohio, USA.

[8 ] Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

[9 ] Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.

[10 ] Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, Peoples Republic of China.

[11 ] Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

[12 ] Division of Clinical Pharmacology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA.

[13 ] Department of Clinical Chemistry, Erasmus MC Rotterdam, The Netherlands.

[14 ] Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.

[15 ] Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

[16 ] Institute of Medical and Biomedical Education, Renal Medicine, St. George's, University of London, London, UK.

Article

Mid ID: NIHMS670362

DOI: 10.1002/cpt.113

PubMed ID: 25801146

SO-VID: 597fabd0-b6c2-4d95-bad0-6c3bbbe888bb

History

Data availability:

Comments

Comment on this article

scite_

Cited by 175

See all cited by